vNAR pharmaceuticals are highly bioavailable and stable, hard targets more accessible for them
Our pharmaceuticals has not side effects and immunogenicity - they have high specificity and small size
For R&D and production of our active molecules needed less resources - that is good for price
At 420 million years, the variable domain of New Antigen Receptors or VNARs are undoubtedly the oldest (and smallest) antigen binding single domains identified in the vertebrate kingdom. Their role as an integral part of the adaptive immune system of sharks has been well established and has served to provide a greater understanding of the evolution of humoral immunity; their cellular components and processes as well as the underlying genetic organization and molecular control mechanisms. Intriguingly, unlike the variable domain of the camelid heavy chain antibodies or VHH, VNARs do not conform to all of the characteristic properties of classical antibodies with an ancestral origin that clearly distinguishes them from true immunoglobulin antibodies. However, this uniqueness of their origin only adds to their potential as next generation therapeutic biologics with their structural and functional attributes and commercial freedom all enhancing their profile and current success. In fact their small size, remarkable stability, molecular flexibility and solubility, together with their high affinity and selectivity for target, all reinforce the potential of these domains as drug candidates.
The development of a platform for the creation of specific inhibitors based on variable fragments of shark antibodies is provided with the grant support of the SKOLKOVO Foundation.
We are a team of competent professionals in our field. Our research соmpany is located in Moscow, Russia. We cooperate with companies from Europe, America and Asia. International communicatio help us to apply the best practices from all the world.
We develop innovative target-oriented pharmaceuticals that combine the best characteristics of modern biopharmaceuticals (antibody and proteins) and traditional small molecules.
Our goal is to achieve a fundamental change in the quality of life of people, to ensure the safety and effectiveness of our drugs, while maintaining access to treatment for society. We develop medicines for such important diseases as atherosclerosis, cancer and autoimmune diseases.
Our company is constantly developing and growing. We are open for collaboration with other institutes and companies. You can work with us, we are looking for scientists with work experience in protein engeneering and antibody engeneering.
If you want to contact us, fill out the contact form on our website. Have a nice day!
Tel.: +7 (916) 809-55-59
Tel.: +7 (999) 851-85-91
Moscow, Skolkovo Center
Bolshoy Boulevard, 42, bldg. 1, Apt. 377